Phase I, Initial Safety/Toxicity Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdCUCD40L) to Patients With Stage III or IV Esophageal Carcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 04 May 2016
At a glance
- Drugs CD154 gene therapy (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- 02 May 2016 Planned End Date changed from 1 Jun 2029 to 1 Jul 2010.
- 02 May 2016 Planned primary completion date changed from 1 Jun 2029 to 1 Jul 2010.
- 04 Aug 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.